Battle looms at Biogen as Icahn seeks board seats
480264
Billionaire investor Carl Icahn said on Monday he is seeking three seats on the board of Biogen Idec Inc , setting the stage for a battle for control of one of the world's biggest biotechnology companies.
594658
Fund manager Brandes Investment  Partners LP said on Friday it intended to vote against  billionaire investor Carl Icahn's proposed $2.31 billion buyout  offer for Lear Corp. , which the auto parts maker has  accepted.
226932
Billionaire financier Carl Icahn offered to buy Mylan Laboratories Inc., the largest US maker of generic medicines, for about $5.38 billion to block Mylan&#39;s proposed purchase of King Pharmaceuticals Inc.
723657
Could a jointly marketed drug lead to a joint company? Ireland&#39;s Sunday Tribune said yesterday that US pharmaceuticals company Biogen Idec (nasdaq: BIIB - news - people ) was looking to make an all-stock bid
599973
Investor Carl Icahn issued a $20-per-share bid to acquire Mylan Laboratories Inc. on Friday and said &quot;at least&quot; three other potential buyers in the generic drug industry could offer more.
360232
Veteran financier Carl Icahn said it was &quot;reprehensible and insulting&quot; that the board of drug maker Mylan Laboratories Inc.
604932
Washington area biotech companies will face pivotal moments this year, finding out whether key products work before money dries up, fending off competition from bigger companies,  and, perhaps filing to go public.-The Washington Post
635618
KANSAS CITY, Missouri  - Opponents of biotech crops said on Wednesday they were filing a lawsuit to challenge the USDA's deregulation of Monsanto Co's genetically engineered sugar beet because of fears of "biological contamination" and other harm to the environment.
231400
WASHINGTON -- Biotechnology lobbyists attempting to slow the development of cheap generic versions of the world's most expensive drugs have been emphasizing questions about their safety in an effort to win support among the new Democratic leaders of Congress.
289215
Robert Klein, real estate developer and champion of stem cell research, is elected chair of the Institute of Regenerative Medicine. Despite isolated grumblings, as the only nominee, he was a shoo-in. Kristen Philipkoski reports from San Francisco.
337666
SAN FRANCISCO -- Billionaire investor Carl C. Icahn was given clearance by US antitrust regulators to purchase shares in Biogen Idec Inc., the world's biggest maker of drugs for multiple sclerosis.
468718
Angry at what they say is an unfairly priced takeover attempt by Genzyme Corp. , more than three dozen small shareholders of a New York biotechnology firm are trying to band together to block Genzyme's deal to buy the company.
524852
The biopharma's outlook is cloudy due to stiffer competition in biomanufacturing.
665690
The developing biopharmaceutical company announces a share offering.
768370
Billionaire investor Carl Icahn yesterday offered to purchase Mylan Laboratories for $20 per share, part of his plan to derail the Canonsburg generic drug maker&#39;s proposed acquisition of King Pharmaceuticals.
193614
The $73.5 billion global biotech business may soon have to grapple with a discovery that calls into question the scientific principles on which it was founded.
639540
PITTSBURGH Carl Icahn, the largest shareholder of Mylan Laboratories, is now threatening to push for new company directors to stop the generic drug maker&#39;s four (B) billion-dollar takeover bid of King Pharmaceuticals.